Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its’s blockbuster cancer drug, offering a faster alternative to IV infusion, according to Endpoints News.

The approval followed a non-inferiority trial, showing Keytruda Qlex works as